About GQ Bio
GQ Bio is a Healthcare company based in Hamburg (Germany) founded in 2012, and was acquired by Pacira in February 2025. The company has 2 employees. Its chief executive, as recorded, is Kilian Guse. GQ Bio offers products and services including Gene Therapy Vector Platform and Transformative Medicines. Its focus areas include Life Sciences, Orthopedics, Drugs and Osteoarthritis. Its legal entity is GQ Bio Therapeutics GmbH.
Company details
Developer of gene therapies for orthopedic treatment. It offers a gene therapy vector platform that develops transformative medicines which include GQ-501, GQ-401, and GQ-203 to treat chronic diseases such as osteoarthritis and intervertebral disc degeneration.
- Headquarters Hamburg, Germany
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website gq-biotx.com/home-2.html
- Social LinkedIn X
- Acquired by Pacira (Feb 2025)
- Legal Name Gq Bio Therapeutics Gmbh
Products & Services of GQ Bio
GQ Bio offers a comprehensive portfolio of products and services, including Gene Therapy Vector Platform and Transformative Medicines.
Enables efficient delivery of large genes for chronic diseases.
Develops treatments for conditions like osteoarthritis.
Investors in GQ Bio
GQ Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Pacira.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Injectable non-opioid products for post-surgical pain control are developed. | 2006 | pacira.com | Parsippany Troy Hills, United States |
Investor details for GQ Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GQ Bio
1 people are tracked at GQ Bio (1 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Kilian Guse | CEO | Leadership |
Complete people profiles for GQ Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GQ Bio
2 dated milestones of GQ Bio across 13 years, from founding to its latest funding, stage changes and deals.
- Founded GQ Bio is founded.
- Exit Acquired by Pacira.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gq Bio
Complete news archive for GQ Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GQ Bio
GQ Bio was founded in 2012.
GQ Bio is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Kilian Guse is the CEO of GQ Bio, as recorded in our data.
GQ Bio has 2 employees.
Developer of gene therapies for orthopedic treatment. It offers a gene therapy vector platform that develops transformative medicines which include GQ-501, GQ-401, and GQ-203 to treat chronic diseases such as osteoarthritis and intervertebral disc degeneration.
GQ Bio offers Gene Therapy Vector Platform and Transformative Medicines.
GQ Bio has 1 investor. Key investors include Pacira.
GQ Bio operates through Gq Bio Therapeutics Gmbh.
Yes. GQ Bio was acquired by Pacira in February 2025.